Aristotle Capital Boston LLC Sells 70,770 Shares of Supernus Pharmaceuticals, Inc. $SUPN

Aristotle Capital Boston LLC reduced its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 23.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 234,503 shares of the specialty pharmaceutical company’s stock after selling 70,770 shares during the quarter. Aristotle Capital Boston LLC owned approximately 0.41% of Supernus Pharmaceuticals worth $11,655,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Freestone Grove Partners LP bought a new position in Supernus Pharmaceuticals in the fourth quarter worth $9,757,000. ADAR1 Capital Management LLC lifted its position in Supernus Pharmaceuticals by 106.3% in the fourth quarter. ADAR1 Capital Management LLC now owns 29,742 shares of the specialty pharmaceutical company’s stock worth $1,478,000 after purchasing an additional 15,324 shares during the period. Cetera Investment Advisers bought a new position in Supernus Pharmaceuticals in the fourth quarter worth $255,000. Jain Global LLC bought a new position in Supernus Pharmaceuticals in the fourth quarter worth $6,128,000. Finally, Amundi lifted its position in Supernus Pharmaceuticals by 107.4% in the fourth quarter. Amundi now owns 20,959 shares of the specialty pharmaceutical company’s stock worth $1,042,000 after purchasing an additional 10,855 shares during the period.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on SUPN. Craig Hallum set a $65.00 price objective on Supernus Pharmaceuticals in a report on Wednesday, February 25th. Weiss Ratings reissued a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a report on Friday, March 27th. Zacks Research raised Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday, April 27th. Finally, Wall Street Zen cut Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 23rd. Four analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $62.17.

Supernus Pharmaceuticals Stock Performance

Shares of NASDAQ SUPN opened at $43.58 on Thursday. The stock has a market cap of $2.53 billion, a PE ratio of -85.45, a PEG ratio of 0.93 and a beta of 0.55. The business has a fifty day moving average of $48.27 and a two-hundred day moving average of $49.51. Supernus Pharmaceuticals, Inc. has a 52-week low of $30.83 and a 52-week high of $59.68.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.